CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 250 enrolled
Drug / intervention
IncobotulinumtoxinA +1 moredrug
Likely dose
IncobotulinumtoxinA 0.1 mLfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02096081
NCT02096081Phase 4Completed
CompareCT.gov

The Treatment of Glabellar Frown Lines

Merz North America, Inc.·interventional·Posted Mar 26, 2014·Updated Oct 19, 2017

In Brief

A Phase 4 clinical trial evaluating IncobotulinumtoxinA and OnabotulinumtoxinA for Glabellar Frown Lines. Completed, enrolled 250 participants across 10 sites.

Detailed Summary

The purpose of this study is to show that two FDA-approved botulinum toxin drugs called Xeomin® and Botox® can reduce the severity of vertical lines (wrinkles) that appear between the eyebrows (glabellar frown lines).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsGlabellar Frown Lines
CountriesUnited States
Collaborators--

Timeline

Phase 4CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedMar 26, 2014
Enrollment StartFeb 1, 2014
Primary CompletionAug 1, 2014
Study CompletionNov 1, 2014
TodayJul 2, 2026
Enrollment to primary: 6 monthsPosted 12.3 years ago

Interventions

IncobotulinumtoxinAdrug

20U injection: equal aliquots of 0.1 mL (4U) to 5 injection points; mode of application: intramuscular injection

OnabotulinumtoxinAdrug

20U injection: equal aliquots of 0.1 mL (4U) to 5 injection points; mode of application: intramuscular injection